Ixazomib and dexamethasone in high risk smoldering multiple myeloma: A clinical and correlative pilot study.

Sham Mailankody,Meghan Salcedo,Elizabet Tavitian,Neha Korde,Nikoletta Lendvai,Hani Hassoun,Alexander M. Lesokhin,Oscar B. Lahoud,Eric L. Smith,Malin Hultcrantz,Sean M. Devlin,Ola Landgren

Ixazomib and dexamethasone in high risk smoldering multiple myeloma: A clinical and correlative pilot study.

2019

Sham Mailankody
Meghan Salcedo
Elizabet Tavitian
Neha Korde
Nikoletta Lendvai
Hani Hassoun
Alexander M. Lesokhin
Oscar B. Lahoud
Eric L. Smith
Malin Hultcrantz
Sean M. Devlin
Ola Landgren

8051Background: Patients with high risk smoldering multiple myeloma (HR-SMM) have an increased risk of progression to multiple myeloma (MM)- median time < 2 years. The standard management of these ...

Keywords:

Pathology
Ixazomib
Dexamethasone
Oncology
Multiple myeloma
Medicine
Internal medicine
median time
increased risk

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations